Edwards Lifesciences Corp (EW.N)
70.16USD
1:30am IST
$-0.32 (-0.45%)
$70.48
$70.47
$70.48
$69.69
168,262
266,989
$110.79
$62.35
EW.N
About
Overall
| Beta: | 0.49 |
| Market Cap (Mil.): | $7,961.54 |
| Shares Outstanding (Mil.): | 112.96 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
Edwards lowers outlook as sales disappoint; shares dive
- Edwards Lifesciences Corp on Tuesday lowered its 2013 outlook due to sluggish sales at the start of the year for its less-invasive replacement heart valves, and its shares plunged 15 percent after hours.
BRIEF-Edwards Lifesciences drops 14.6 percent in extended trade
NEW YORK, April 23 - Edwards Lifesciences Corp : * Drops 14.6 percent to $70.75 in extended trade after Q1 results, outlook
UPDATE 1-Edwards lowers outlook as sales disappoint; shares fall
* U.S. 1st-qtr sales of Sapien heart valves were below expectations
Edwards profit up on special payment; lowers outlook
April 23 - Edwards Lifesciences Corp said on Tuesday first-quarter net earnings more than doubled, boosted by a large gain from patent litigation with Medtronic Inc , but the heart valve maker lowered its 2013 outlook due to sluggish sales at the start of the year.
Edwards heart valve system good as surgery at 3 years-trial
SAN FRANCISCO - Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three years as those who had open-heart surgery, with no increased risk of stroke, according to results from a clinical trial.
UPDATE 3-Edwards heart valve system good as surgery at 3 years-trial
* Three-yr death rate 44.2 pct for Sapien, 44.8 for surgery
Edwards heart valve system as good as surgery after 3 years -trial
SAN FRANCISCO, March 11 - Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three years as those who had open-heart surgery, with no increased risk of stroke, according to results from a clinical trial.
BRIEF-Death rate for Edwards Lifesciences' device and surgery identical after three years-study
March 11 - Edwards Lifesciences Corp : * Death rate for Edwards lifesciences' sapien heart valve system and
Redesigned Edwards heart valve shows improvement in study
SAN FRANCISCO - A smaller, redesigned version of Edwards Lifesciences' non-invasive heart valve replacement system called Sapien XT performed well and led to fewer complications than the original Sapien, according to data from a clinical trial presented on Sunday.
UPDATE 1-Redesigned Edwards heart valve shows improvement in study
* Sapien XT, Sapien show similar death, stroke rates at 1 yr * Fewer complications seen with newer XT model after 30 days By Bill Berkrot SAN FRANCISCO, March 10 - A smaller, redesigned version of Edwards Lifesciences' non-invasive heart valve replacement system called Sapien XT performed well and led to fewer complications than the original Sapien, according to data from a clinical trial presented on Sunday. Both versions, known as transcatheter aortic valve replacem
Competitors
| Price | Change | |
|---|---|---|
| Medtronic, Inc. (MDT.N) | $52.92 | -0.59 |
| St. Jude Medical, Inc. (STJ.N) | $45.87 | +0.21 |
| Sorin SpA (SORN.MI) | €1.95 | -0.01 |
| ICU Medical, Incorporated (ICUI.OQ) | $74.17 | +0.14 |
| Pulsion Medical Systems SE (PUSG.F) | €13.06 | -0.14 |
| LiDCO Group plc (LID.L) | 12.75p | 0.00 |
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
